**Abstract:** B-cell chronic lymphocytic leukemia (CLL) results from intrinsic genetic defects and complex microenvironmental stimuli that fuel CLL cell growth through an array of survival signaling pathways. Novel small-molecule agents targeting the B-cell receptor pathway and anti-apoptotic proteins alone or in combination have revolutionized the management of CLL, yet combination therapy carries significant toxicity and CLL remains incurable due to residual disease and relapse. Single-molecule inhibitors that can target multiple disease-driving factors are thus an attractive approach to combat both drug resistance and combination-therapy-related toxicities. We demonstrate that SRX3305, a novel small-molecule BTK/PI3K/BRD4 inhibitor that targets three distinctive facets of CLL biology, attenuates CLL cell proliferation and promotes apoptosis in a dose-dependent fashion. SRX3305 also inhibits the activation-induced proliferation of primary CLL cells in vitro and effectively blocks microenvironment-mediated survival signals, including stromal cell contact. Furthermore, SRX3305 blocks CLL cell migration toward CXCL-12 and CXCL-13, which are major chemokines involved in CLL cell homing and retention in microenvironment niches. Importantly, SRX3305 maintains its anti-tumor effects in ibrutinib-resistant CLL cells. Collectively, this study establishes the preclinical efficacy of SRX3305 in CLL, providing significant rationale for its development as a therapeutic agent for CLL and related disorders.

**Keywords:** chronic lymphocytic leukemia; targeted small molecule inhibitor; B-cell receptor signaling; BTK; PI3K; BET/BRD4 proteins

---

1. **Introduction**

Chronic lymphocytic leukemia (CLL) is characterized by the expansion of mature B-cells that accumulate in the blood, bone marrow (BM), and secondary lymphoid organs such as the lymph node (LN) and spleen. Hallmark features of CLL include amplified B-cell receptor (BCR) signaling, defective apoptosis, profound tumor microenvironment (TME) dependency, and immune dysfunction [1,2]. Novel therapies targeting BCR signaling (e.g., ibrutinib and idelalisib) and B-cell leukemia/lymphoma-2 (BCL-2) family proteins (e.g., venetoclax) provide significantly improved outcomes for both previously untreated
CLL patients and those with adverse disease (e.g., 17p deletion and/or TP53 mutation or complex karyotype). Unfortunately, patients continue to progress on these agents by developing acquired resistance through multiple mechanisms [3].

Bruton tyrosine kinase (BTK) inhibitors (e.g., ibrutinib, acalabrutinib, zanubrutinib) disrupt effective BCR signaling, which is vital to CLL cell proliferation and supportive TME interactions [4,5]. BTK inhibition elicits high response rates and durable remission in CLL patients, including those with 17p deletion [del(17p)], but does not fully eliminate the disease [3,6]. Studies have shown that the persistent activation of PI3K-AKT-mTOR, NF-κB, and/or MYC signaling contributes to acquired resistance to ibrutinib and residual disease [7–10]. Relapse on ibrutinib is frequently due to BTK mutations that prevent inhibitor binding and often lead to the development of more aggressive diseases such as relapse/refractory CLL or Richter Transformation (RT) [11,12] from CLL into diffuse large B-cell lymphoma (DLBCL-RT) [13]. Other inhibitors targeting phosphatidylinositol-3 kinases (PI3K) or anti-apoptotic pathways through BCL-2 inhibition can be used to further disrupt proliferation/survival signaling and defective apoptosis in CLL [12]. However, these therapies often require combination with other agents, including monoclonal antibodies, to elicit durable responses with varied toxicity [3,12]. Despite these advances, CLL remains an incurable malignancy, and relapse post-BTK and/or BCL-2 inhibitor therapy is a major clinical challenge in need of novel therapies.

Combination strategies targeting different facets of CLL biology used earlier in disease management may result in lower rates of emergence of drug-resistant clones [14,15]. Epigenetic dysregulation plays a central role in cancer pathogenesis [16–18], making strategies that therapeutically target abnormal epigenetic factors an area of active investigation. For instance, aberrations in epigenetic modifiers (e.g., BRD4, CREBBP) have been identified as early driving events in lymphomagenesis and relapse-associated events including chemoresistance and immune escape [19]. Bromodomain-containing protein 4 (BRD4), a member of the bromodomain and extra-terminal (BET) family of epigenetic reader proteins, binds to acetylated histones to facilitate the recruitment of transcriptional machinery [20]. Cancer cells display exceptionally higher BRD4 binding at super-enhancers of genes that are crucial to maintaining cancer cell identity and promoting oncogenic gene transcription [21,22]. By doing so, BRD4 regulates the expression of genes that govern cell growth and evasion of apoptosis in cancer (e.g., MYC, BCL6, BCL2, and CDK4/6) [22–25]. Furthermore, histone-independent roles for BET proteins are relevant in leukemia/lymphoma cell survival, as BRD4 interacts with acetylated RELA [26], which augments NF-κB signaling, a central mediator of both external TME triggers and cell-intrinsic aberrations in CLL [27]. Currently available small-molecule BET inhibitors competitively bind to the acetyl-lysine recognition pocket of BET bromodomains, displacing BET proteins from active chromatin, which in turn reduces associated gene expression [28,29].

Recently, BRD4 was reported to be overexpressed in primary CLL cells compared to normal B-cells [30]. In that study, BRD4 was enriched at hallmark genes implicated in CLL disease biology and progression such as genes associated with BCR pathways (e.g., BTK, BLK, SYK, PLCG2, and PIK3CG), ZAP70, CXCR4, MIR155, IL4R, IL21R, IKZF1, and TCL1A [30]. BET inhibition has demonstrated preclinical activity in various leukemia and lymphoma models [31], including CLL. Novel BET inhibitors (e.g., PLX51107, OTX015, and GS-5829) were reported to reduce CLL cell proliferation, induce cell cycle arrest, and promote cell apoptosis in vitro even in the presence of TME protection [30,32]. Moreover, BET inhibition significantly decreased tumor burden and prolonged survival in murine models of aggressive CLL [30]. Despite the remarkable preclinical activity of BET inhibitors in hematological malignancies, studies to identify beneficial combination therapy approaches to enhance efficacy have been reported [31]. As expected, synergism was observed when combining BET inhibitors (e.g., BAY 1238097, GS-5829, OTX015) with inhibitors of BTK (ibrutinib), SYK (entospletinib), PI3K (copanlisib, idelalisib), or BCL2 (venetoclax) in preclinical models of CLL [32–34] and DLBCL-RT [35]. Interestingly, the anti-leukemic activity of the BET inhibitor, GS-5829, proved to be synergistic in combination with ibrutinib or
idelalisib in primary CLL/nurse-like cell co-cultures reflective of the LN TME in CLL [32]. Simultaneous targeting of different components of BCR signaling and BET proteins may permit less opportunity for resistance mechanisms to develop, which could translate into more durable patient responses and disease control.

We recently introduced thienopyranone (TP) scaffold-based chemotypes [36] for the combinatorial inhibition of BTK, PI3K-AKT, and BRD4-MYC in a single compound (i.e., SRX3262 and SRX3305) and demonstrate impressive preclinical activity in mantle cell lymphoma (MCL) [37,38]. BTK/PI3K/BRD4 triple-inhibitors present a potential solution to the toxicity that often plagues combination therapeutic strategies that are necessary to overcome CLL progression and drug resistance. Importantly, our studies demonstrated that these novel multi-action inhibitors yield potent anti-tumor effects but spare healthy bystander cells and are less toxic to healthy donor B-cells than the combination of single-target drugs required to effectively inhibit the same three targets. In this study, we extend our evaluation of SRX3305 to include preclinical models of CLL and DLBCL, including ibrutinib-resistant CLL, further validating the efficacy of a multi-target single-molecule approach to overcome TME- and drug-induced resistance mechanisms in B-cell malignancies.

2. Results

2.1. SRX3305 Inhibits Proliferation and Induces Apoptosis of Malignant B-Cell Lines

The anti-proliferative properties of SRX3305 or SRX3262 (first-generation BTK/PI3K/BRD4 triple-inhibitor) were first evaluated in a panel of B-cell non-Hodgkin lymphoma (B-NHL) cell lines representative of CLL (OSU-CLL, HG-3, MEC-1, and MEC-2) and DLBCL (OCI-LY3 and SU-DHL-6). Key cell line characteristics/genetic aberrations are summarized in Supplementary Table S1 [39–47]. SRX3305 and SRX3262 significantly inhibited CLL cell proliferation in a dose-dependent manner (Figure 1A–D). We report an average IC\textsubscript{50} of 1.38 \(\mu\)M for SRX3305 and 2.98 \(\mu\)M for SRX3262 across the CLL lines evaluated. SRX3305 appeared to be superior to SRX3262 (on average 2.5-fold more potent, \(p < 0.05\)) and hence was used for all further studies. SRX3305 is at least equipotent to common single-target inhibitors (ibrutinib, idelalisib, JQ1, or OTX015) evaluated on this panel of B-NHL cells. Similarly, SRX3305 reduced cell proliferation in DLBCL cells (Supplementary Figure S1) with IC\textsubscript{50} values of \(~290\) nM in OCI-LY3 cells (activated B-cell DLBCL subtype) and \(~920\) nM in SU-DHL-6 cells (germinal center DLBCL subtype). We next demonstrate that SRX3305 induces apoptosis in HG-3 and OSU-CLL cells in a dose-dependent manner at 24 h (Figure 1E,F), and a similar trend was witnessed at 48 h (data not shown). This indicates that SRX3305 not only induces a cytostatic effect, but also a cytotoxic effect in CLL cells.

![Figure 1. Cont.](image-url)
SRX3305 is cytotoxic to CLL cells in a dose-dependent manner. Four CLL cell lines, OSU-CLL (A), HG-3 (B), MEC-1 (C), and MEC-2 (D), were treated with increasing concentrations of SRX3262, SRX3305 (BTK/PI3K/BRD4 triple-inhibitor), ibrutinib (BTK inhibitor), idelalisib (PI3K inhibitor), or JQ1 (BET inhibitor) for 72 h. Proliferation was assessed via MTS assay, and results are given as % proliferation normalized to vehicle. Error bars indicate SEM (n = 3 independent experiments per cell line). IC_{50} values (mean ± SEM) are noted for each inhibitor within the in-figure legends. Dose-dependent decrease in CLL cell proliferation is observed with asterisks denoting significance vs. vehicle. (E) OSU-CLL and (F) HG-3 cells were treated with DMSO vehicle (Veh), SRX3305 (0.5, 1, 2 µM), ibrutinib (Ibr, 1 µM), idelalisib (Idel, 1 µM), or JQ1 (0.5 µM) for 24 h. Percentage of apoptosis (annexin V-positive cells) was evaluated via flow cytometry (n = 3 independent experiments per cell line). Results are given as mean ± SEM. Asterisks denote significant inhibitor-induced apoptosis vs. control vehicle. * p < 0.05, ** p < 0.01, *** p < 0.001.

2.2. SRX3305 Inhibits Critical BCR Survival Signaling in CLL

Two major targets of SRX3305, BTK and PI3K, are vital to BCR survival and proliferation signaling [48]. The third, BRD4, is critical for the transcriptional regulation of numerous factors driving CLL pathogenesis, including MYC [23,30]. We show that SRX3305 effectively inhibits the phosphorylation of BTK and PRAS40 (indicative of PI3K/AKT signaling) and reduces MYC expression in OSU-CLL, MEC-1 and MEC-2 cells (Figure 2A). Single-target inhibitors (ibrutinib, idelalisib, JQ1) were used as controls.

Next, we sought to examine the effects of SRX3305 under activation-induced BCR signaling. Following inhibitor treatment for 4 h, OSU-CLL and MEC-1 cells were stimulated with anti-IgM in the last 15 min. In parallel, inhibitor washout experiments were conducted to further evaluate whether inhibitor-induced target modulation could be maintained. CLL cells were subject to inhibitor treatment for 1 h prior to inhibitor washout. Three hours later, the cells were stimulated with anti-IgM (last 15 min) to elicit BCR crosslinking. In these studies, ibrutinib, a covalent irreversible BTK inhibitor, and the noncovalent reversible BTK inhibitor BMS-935177 were used as controls. As expected, continuous inhibitor treatment resulted in decreased phosphorylation of BTK (p-BTK) and PRAS40 (p-PRAS40) and reduced MYC expression in BCR-activated CLL cells. CLL cells treated with SRX3305 or
ibrutinib (covalent BTK inhibitor) also retained the inhibition of p-BTK following treatment washout, while cells treated with the reversible inhibitor BMS935177 regained BTK phosphorylation. Notably, SRX3305-treated cells maintained marked inhibition of p-PRAS40 and MYC expression after treatment washout (Figure 2B), whereas these effects were lost in ibrutinib-treated cells. In comparison to OSU-CLL cells, MEC-1 cells that harbor del(17p) (Supplementary Table S1) appeared less sensitive to maintained SRX3305-mediated down-regulation of p-PRAS40 in the washout condition. This may be due to reduced sensitivity of del(17p) CLL cells to PI3K/AKT inhibition as previously reported [49]. In spite of the modest modulation of p-PRAS40 in the MEC-1 washout conditions, SRX3305 still maintained prominent modulation of other oncogenic factors (p-BTK, MYC), indicating the therapeutic benefit of this triple-inhibition in high risk del(17p) CLL.

**Figure 2.** SRX3305 modulates critical B-cell survival pathways in CLL. (A) CLL cell lines (OSU-CLL, MEC-1, and MEC-2) were treated with DMSO vehicle (Veh), SRX3305 (0.5, 1, 2 µM), ibrutinib (Ibr, 1 µM), idelalisib (Idel, 1 µM), or JQ1 (0.5 µM). After 4 h, whole-cell lysates were collected and analyzed for phosphorylation and expression of the given proteins, indicative of modulation of BTK (p-BTK/BTK), PI3K (p-PRAS40/PRAS40), and BET/BRD4 (MYC). GAPDH serves as a loading control (n = 3 independent experiments per cell line). Representative immunoblots are shown. (B) OSU-CLL and MEC-1 cells were treated with DMSO vehicle (Veh), SRX3305 (0.5, 1, 2 µM), 1 µM ibrutinib (Ibr; irreversible BTK inhibitor), or 1 µM BMS-986142 (BMS; reversible BTK inhibitor). Cells were either incubated with treatment continuously for 4 h (Continuous Tx), or treatment was washed out after 1 h and replaced with fresh media for the remaining 3 h of incubation (Wash-out Tx). The stimulation of BCR signaling was performed via the addition of 10 µg/mL anti-IgM for the last 15 min (+α-IgM). Whole-cell lysates were then analyzed for expression or phosphorylation of the indicated proteins (n = 3 independent experiments per cell line). β-Tubulin serves as a loading control. Representative immunoblots are shown for each cell line. Numbers below the bands represent densitometric quantification relative to loading control, total protein (for phosphorylated proteins), and normalized to Veh (for (A)) or +α-IgM Veh (for (B)).
2.3. SRX3305 Inhibits Primary Malignant B-Cell Survival and Proliferation

To mimic conditions within pseudo-proliferation centers where CLL expands [50], we evaluated SRX3305 in primary CLL cells stimulated with CpG oligodeoxynucleotides (CpG ODN), a well-known Toll-like receptor 9 agonist that promotes ex vivo CLL cell proliferation [51]. Characteristics of the patients’ samples are summarized in Supplementary Table S2. SRX3305 markedly decreased CpG ODN-induced proliferation of primary CLL cells in a dose-dependent manner (Figure 3A). Immunoblot analysis showed that SRX3305 reversed CpG ODN-mediated proliferation reflected by reduced MYC levels in primary CLL cells (Figure 3B). In parallel, SRX3305 induced the accumulation of P21 (cyclin-dependent kinase inhibitor), indicative of cell cycle arrest [52] (Figure 3B). SRX3305 did not influence the proliferation of patient-derived CLL cells under unstimulated/basal conditions (data not shown).

![Graph](image)

**Figure 3.** Antitumor effects of SRX3305 in primary CLL samples. (A) Patient-derived CLL cells (n = 8) were treated with the indicated concentrations of SRX3305; 1 µM of ibrutinib (Ibr), idelalisib (Idel), or JQ1; or DMSO vehicle. They were then stimulated with CpG oligodeoxynucleotides (+CpG; 3.2 µM)
for 48 h. Proliferation was assessed via MTS assay, and results are given as % proliferation normalized to mean stimulated vehicle (+CpG Veh). Red lines indicate average values. *p values indicate significance vs. stimulated vehicle. (B) Patient-derived CLL cells (n = 6) were treated with DMSO vehicle or the indicated SRX3305 concentrations for 4 h in the presence of CpG oligonucleotides (+CpG, 3.2 µM). The protein expression of MYC and P21 was determined by immunoblot analysis. GAPDH serves as a loading control. Representative immunoblots from three patients are shown. Numbers below the bands represent densitometric quantification relative to loading control and normalized to +CpG Veh. (C) Lymphocytes isolated from spleens of terminally diseased Eµ-TCL1 (n = 6–12) or Eµ-Myc/TCL1 (n = 6–14) mice were stimulated with 1 × PMA/Ionomycin (+PMA/Iono) and treated with DMSO vehicle or increasing concentrations of SRX3305 as indicated, or 1 µM Ibr, Idel, or JQ1. Proliferation was assessed via MTS assay 48 h later, and results are given as % proliferation normalized to mean stimulated vehicle (+PMA/Iono Veh). Red lines indicate averages. *p values indicate significance vs. stimulated vehicle. *p < 0.05, **p < 0.01, ***p < 0.001.

We next investigated SRX3305-induced cytotoxicity on tumor cells derived from murine models of aggressive B-cell leukemia and lymphoma. We utilized malignant B-cells isolated from Eµ-TCL1 [53,54] (CLL model) and Eµ-Myc/TCL1 mice [55,56] (concurrent CLL and B-cell lymphoma model). Primary murine spleen-derived tumor samples (comprising >90% malignant B-cells) were cultured ex vivo under mitogenic stimulation (PMA/ionomycin). SRX3305 treatment induced significant cytotoxicity in Eµ-TCL1 and Eµ-Myc/TCL1-derived malignant cells in a dose-dependent manner (Figure 3C), suggesting promising therapeutic benefits in aggressive CLL and associated lymphomas (e.g., DLBCL-RT). As expected, SRX3305 was more effective than the single-target inhibitors (ibrutinib, idelalisib, JQ1) in primary malignant B-cells.

2.4. SRX3305 Disrupts Stroma Survival Support and Chemokine-Induced Migration in CLL

Given the importance of the TME in CLL pathogenesis and therapy resistance [57,59,59], we sought to evaluate the efficacy of SRX3305 in the presence of stroma protection. The clinical efficacy of inhibitors targeting BCR signaling is partially attributed to disrupting CLL–cell interactions with its TME [60]. As expected, the co-culture of primary CLL cells on BM-derived stromal cells protects them from spontaneous apoptosis [59], resulting in a significant increase in CLL cell viability. Notably, treatment with SRX3305 reduced CLL cell viability in a dose-dependent manner despite stroma protection (Figure 4A). This was comparable to CLL therapeutics, ibrutinib, or idelalisib. Of note, SRX3305 was not toxic to the stromal cells (Supplementary Figure S2), indicating that SRX3305-induced CLL cell cytotoxicity is not a function of reduced stroma viability.

CLL cell migration, homing to supportive TME niches, and retention therein have been reported to support leukemic cell survival and disease progression [61,62]. We therefore investigated if SRX3305 could inhibit CLL cell migration towards key chemokines secreted by protective stromal cells in the BM (CXCL-12) and secondary lymphoid tissues (CXCL-13) [63–65]. Using a trans-well assay system, we demonstrate that SRX3305 reduced the migration of MEC-1 cells towards CXCL-12 or CXCL-13 (Figure 4B,C), further indicating that SRX3305 can disrupt CLL cell trafficking to supportive niches. Similar findings were seen in preclinical studies of the highly active BCR-targeting CLL therapeutic ibrutinib [4,66]. These findings suggest that SRX3305 can overcome TME-induced survival signaling, an established mediator in resistance to therapy in CLL.
SRX3305 disrupts TME-induced CLL cell survival and migration. (A) Primary CLL cells (n = 9 patients) were co-cultured with murine 9-15c bone marrow-derived stromal cells and incubated with increasing amounts of SRX3305 (0.5, 1, 2 µM), ibrutinib (Ibr, 1 µM), or idelalisib (Idel, 1 µM). After 48 h, CLL cell viability was determined by annexin V/PI staining, and cells negative for both annexin V and PI were declared to be viable. Red lines indicate average values. Significant dose-dependent decrease in CLL viability following SRX3305 treatment on stromal support is observed with asterisks denoting significance vs. vehicle control. (B, C) MEC-1 cells were treated with DMSO vehicle (Veh), SRX3305 (SRX, 1 µM) or ibrutinib (Ibr, 1 µM) and allowed to migrate for 6 h through trans-well inserts toward 200 ng/mL CXCL-12 (B) or 1000 ng/mL CXCL-13 (C). Chemotaxis index represents the number of cells migrated toward the indicated chemokine divided by the number of cells that migrated with no chemokine present for each treatment condition. Red lines indicate averages (n = 10 independent experiments per chemokine). * p < 0.05, ** p < 0.01, *** p < 0.001.

2.5. SRX3305 Is Active in Ibrutinib-Resistant CLL

We hypothesized that because SRX3305 selectively targets PI3K and BRD4 in addition to BTK, this inhibitor would remain effective against ibrutinib-resistant CLL. To evaluate this in the context of non-genetic acquired drug resistance, we generated an ibrutinib-resistant CLL cell line model by prolonged culture of HG-3 cells with increasing amounts of ibrutinib (Supplementary Figure S3). Remarkably, SRX3305 decreased cell proliferation in ibrutinib-resistant HG3 (IR-HG3) cells (Figure 5A), while the anti-proliferative effects of ibrutinib were attenuated in IR-HG3 cells. These data suggest that SRX3305 has the potential to overcome acquired ibrutinib resistance. Immunoblot analysis revealed that SRX3305 consistently decreased MYC expression and p-PRAS40 (PI3K target) and increased P21 levels in IR-HG3 cells, while ibrutinib demonstrated a partial response and failed to reduce p-PRAS40 (Figure 5B). Overall, BTK activation (phosphorylation) is reduced in the IR-HG3 cell line, suggesting that adaptive kinome reprogramming bypasses the effect of ibrutinib and an increased reliance on alternative survival mechanisms such as PI3K/AKT/ERK [7,67]. Hence, as expected, we observed minimal decrease in BTK phosphorylation upon treatment with SRX3305 or ibrutinib.
Figure 5. SRX3305 is effective in an ibrutinib-resistant CLL model. (A) HG-3 and ibrutinib-resistant HG-3 (IR-HG3) cells were incubated with increasing concentrations of ibrutinib or SRX3305 for 72 h. Proliferation was assessed via MTS assay, and results are given as % proliferation normalized to vehicle. Error bars indicate SEM (n = 6 independent experiments per cell line). A dose-dependent decrease in cell proliferation is observed, with asterisks denoting significance. **p < 0.01, ***p < 0.001. IC50 values are noted for each inhibitor within the in-figure legends (mean ± SEM). (B) Western blot analysis of HG-3 and ibrutinib-resistant HG-3 (IR-HG3) cells (n = 3 independent experiments per cell line) that were treated with DMSO vehicle (Veh), SRX3305 (SRX; 1, 2 µM), or ibrutinib (Ibr; 1 µM) for 4 h and stimulated for the last 15 min with 10 µg/mL anti-IgM (+α-IgM). Representative immunoblots are shown for the phosphorylation and expression of the indicated proteins. HSP90 or GAPDH were used as loading controls. Numbers below the bands represent densitometric quantification relative to loading control, total protein (for phosphorylated proteins), and normalized to +α-IgM Veh.

3. Discussion

Aberrant activities of diverse signaling pathways, including BTK, PI3K-AKT, and MYC-BRD4, contribute to CLL pathogenesis and the persistence of residual disease with treatment. Each of these signaling pathways can be disrupted by the novel single small molecule BTK/PI3K/BRD4 inhibitor, SRX3305. In this study, we evaluated the preclinical efficacy of SRX3305 in CLL. We found that SRX3305 inhibits CLL cell proliferation at significantly lower doses than individual inhibitors of BTK, PI3K, and BRD4. SRX3305 proved to be not only cytostatic but also cytotoxic to CLL cells with marked induction of apoptosis. This response is in part due to irreversible binding of BTK, inhibiting its kinase function and thus significantly impairing BCR signaling. However, malignant B-cells can prioritize other signaling pathways to survive under consistent BTK inhibition. Importantly, SRX3305 also potently and irreversibly impairs phosphorylation of PI3K targets (e.g., PRAS40) and expression of BRD4 targets (e.g., MYC). Remarkably, SRX3305 sustains impressive anti-leukemic properties in ibrutinib-resistant CLL cells. SRX3305 also exhibited potent anti-tumor activity toward primary CLL cells ex vivo. The triple-inhibitor dose-dependently impaired the proliferation of stimulated primary CLL patient-derived B-cells and significantly reduced BTK phosphorylation and MYC expression in CLL cells while inducing P21 expression, indicative of cell cycle arrest. Lastly, SRX3305 significantly inhibited the proliferation of malignant B-cells from Eμ-TCL1 and Eμ-Myc/TCL1 mice ex vivo, suggesting promising therapeutic benefits in aggressive CLL and lymphomas.

CLL cells are highly dependent on diverse supportive stimuli produced by surrounding TME cells, including stromal cells in the BM and secondary lymphoid tissue niches [59]. Crosstalk between malignant and stromal cells in the TME can occur through direct cell-
to-cell contact (via adhesion molecules) or indirectly by soluble factors (e.g., CXCL-12 and CXCL-13) [68]. These interactions lead to the reciprocal activation of BCR and NF-κB pathways, gene expression changes (e.g., increase in MYC and anti-apoptotic proteins), and chemotaxis, resulting in sustained growth/proliferation of leukemic cells and resistance therapeutic agents [69]. In our study, primary CLL cells co-cultured with stromal cells maintained significantly greater viability ex vivo, and this was markedly reduced in the presence of SRX3305. Bidirectional signaling networks within the TME are integral to CLL disease progression and drug response. For instance, CXCL-12/CXCR4 and CXCL-13/CXCR5 are key chemokine networks that promote CLL cell homing to protective lymphoid tissues [63–65]. Inhibiting the BCR signaling pathway with ibrutinib [70] or idelalisib [71] is known to impair BCR- and chemokine-mediated cell adhesion and migration in CLL. Using a trans-well system, we showed that treatment with SRX3305 significantly impairs CLL cell migration toward both CXCL-12 and CXCL-13. Preclinical studies of BET inhibitors in CLL [30,32] suggest that their efficacy may be partially attributed to interference with key CLL/TME interactions including those mediated by chemokine/cytokine networks. Interestingly, BRD4 was enriched at key CLL cell-trafficking genes (CCR7, CXCR4) in primary CLL cells [30]. Our preclinical findings demonstrate that SRX3305 can overcome TME-mediated survival signals, suggesting its efficacy within TME sanctuaries in CLL.

Selective pressure of ibrutinib monotherapy often leads to the development of drug resistance in CLL. Ibrutinib can promote the mutation of cysteine 481 of BTK required for irreversible binding of ibrutinib to BTK. We previously demonstrated that SRX3262 and SRX3305 exhibited cytotoxic effects in malignant B-cells harboring the BTK-C481S mutation [37,38]. In addition to mutations in drug-targeting proteins, several non-genetic mechanisms rendering CLL cells resistant to ibrutinib have been described and usually manifest as upregulation of alternative survival signaling pathways, such as the PI3K/AKT/ERK [67]. Here, we evaluated SRX3305 in the context of acquired resistance to prolonged ibrutinib treatment. Notably, SRX3305 was almost equipotent in ibrutinib-resistant CLL cells and their parental ibrutinib-sensitive counterpart, whereas ibrutinib was significantly less cytotoxic in ibrutinib-resistant cells. Our ibrutinib-resistant CLL cells downregulate BTK activation, suggesting an increased reliance on alternative survival pathways. The phosphorylation of PI3K target PRA540 was inhibited in ibrutinib-resistant and parental CLL cells following SRX3305 treatment. Similarly, MYC expression was equally downregulated in ibrutinib-resistant cells with SRX3305 treatment, illustrating the potential for a triple-inhibitor to bypass the reciprocal activation of alternative survival signaling and overcome single-target drug resistance. These results suggest further evaluation of this novel chemotype in patients with CLL where responses to ibrutinib are partial or have relapse/refractory disease.

Numerous combination therapy approaches have been pursued for the treatment of CLL to combat emergence of drug resistance [14,15]. Preclinical studies have demonstrated that repressing MYC by targeting BET proteins enhances lymphoma cell vulnerability to PI3K inhibitors through the upregulation of several PI3K pathways genes and increased GSK3β phosphorylation, resulting in increased β-catenin protein abundance [72,73], suggesting that combinatory targeting of PI3K with SRX3305 would further promote MYC degradation by allowing GSK3β-dependent MYC phosphorylation [74] and stabilization of the MYC antagonist, MAD1 [75]. Our recent preclinical studies with the first-generation BTK/PI3K/BRD4 inhibitor SRX3262 in MCL demonstrated reduced phosphorylation of MYC at Ser62 and Thr58 [37], which are critical mediators of MYC protein stability and degradation in cancer [74]. Furthermore, earlier studies have reported BET inhibition to be synergistically lethal with ibrutinib in MCL and CLL models [32,76]. PI3K and BTK inhibitors have also been combined to intercept constitutive BCR pathway signaling at multiple points [77]. While combination approaches have shown promising preclinical efficacy, the increased risk of toxicity when combining multiple small-molecule-targeted agents remains an evident concern [38,78]. Individual drugs used to inhibit BTK, PI3K, and BET proteins each have unique side-effect profiles, and as such, additive side-effects from
simultaneous inhibition of these pathways may occur. BTK inhibitors are associated with platelet effects and bleeding, as well as cardiovascular toxicities [79], and PI3K inhibitors carry the risk of inflammatory pneumonitis, liver toxicity, and inflammatory diarrhea [80]. BET inhibition is associated with anemia, thrombocytopenia, and neutropenia in advanced malignancies [81,82]. Combining multiple agents/drugs presents challenges in tailoring therapeutic regimens based on each drug’s unique pharmacokinetic profile (adsorption, distribution, metabolism, and elimination) and additive adverse toxicities [83,84]. A multi-target inhibitor such as SRX3305 provides the advantage of multi-axis inhibition with a single compound that may result in a better toxicity profile and reduced pill burden, which is a major issue impacting the adherence of patients to multi-drug therapeutic regimens. Future studies evaluating the pharmacokinetic and pharmacodynamic effects of this novel class of inhibitors in vivo are needed to delineate the associated toxicities and translational potential of such promising TP-scaffold multi-action inhibitors for the treatment of B-cell malignancies.

4. Materials and Methods

4.1. Cell Lines, Primary Samples, and Inhibitors

Malignant B-cell lines (MEC-1, MEC-2, HG-3, OCI-LY3) were purchased from DSMZ (Braunschweig, Germany), while SU-DHL-6 cells were purchased from ATCC (Gaithersburg, MD, USA). The OSU-CLL cell line [85] was provided by the Human Genetics Sample Bank of The Ohio State University (OSU; Columbus, OH, USA). The murine 9-15c stromal cell line [86] was obtained from RIKEN (Ibaraki, Japan). To generate ibrutinib-resistant cells, HG-3 cells were treated with progressively increasing ibrutinib concentrations (up to 25 µM) over the course of 3 months, as further detailed in the Supplementary Materials. CLL patient samples (peripheral blood mononuclear cells; PBMCs) were obtained from the Leukemia Tissue Bank (OSU) in accordance with the Declaration of Helsinki following informed consent and under a protocol approved by the Institutional Review Board at OSU. In brief, PBMCs from CLL patients were isolated from whole blood through ficoll density gradient centrifugation. Prior to use in experiments, CLL patient-derived samples were confirmed to contain more than 90% CD5+/CD19+ cells by flow cytometric analysis on a NovoCyte 2060R flow cytometer (ACEA Biosciences Inc., San Diego, CA, USA).

Lymphocytes isolated from Eµ-TCL1 and Eµ-Myc/TCL1 mouse spleens were obtained from the Animal Research Facility of the University of Nebraska Medical Center (UNMC), adhering to institutional animal care guidelines. Spleens were harvested from terminally ill mice (i.e., moribund at humane endpoints), and the percentage of malignant B-cells was confirmed via flow cytometry to exceed 90% CD5+/CD19+ prior to experimental use. Fluorochrome-conjugated CD19 and CD5 antibodies were ordered from BD Biosciences (Franklin Lakes, NJ, USA).

Ibrutinib, idelalisib, JQ1, and OTX015 were purchased from Cayman Chemicals. SRX3262 and SRX3305 were synthesized and provided by SignalRx Pharmaceuticals, Inc. (Cumming, GA, USA).

4.2. Cell Culture

Cell lines and primary CLL samples were cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum (hi-FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin (P/S), and 2 µM L-glutamine except for OCI-LY3, which was maintained in Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 20% hi-FBS, P/S, and 55 µM 2-mercaptoethanol. Primary murine splenocytes were cultured in RPMI-1640 supplemented with 10% hi-FBS, P/S, 2 mM L-glutamine, 55 µM 2-mercaptoethanol, 100 µM MEM non-essential amino acid solution, 1 mM sodium pyruvate, and 10 mM HEPES buffer. Hi-FBS was purchased from Avantor® (Radnor, PA, USA). Basal media and supplements were obtained from Life Technologies (Gaithersburg, MD, USA).
4.3. Cytotoxicity and Flow Cytometric Studies

MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assays were used to determine inhibitor-induced cytotoxicity. Briefly, primary cells (~0.7 × 10^6/well) or cell lines (~25,000/well) were treated with vehicle (DMSO) or increasing inhibitor concentrations for up to 72 h in 96-well plates and then the CellTiter 96<sup>®</sup> AQUueous assay (Promega, Madison, WI, USA) was performed according to manufacturer’s instruction to determine cell proliferation. Absorbance signal from each well was acquired at 490 nm on a Tecan Infinite<sup>®</sup> M1000 Pro microplate reader (Männedorf, Switzerland). In addition, cell viability and/or apoptosis was measured by flow cytometry using annexin V/propidium iodide (PI) assay kit from Leinco Technologies (Fenton, MO, USA) as per manufacturer’s protocol. Stromal cell co-culture experiments were performed as previously described by plating a 75 cm<sup>2</sup> flask (90% confluent) in 48-well plate 24 h before adding patient-derived CLL cells (1 × 10<sup>7</sup>/mL).

4.4. BCR Pathway Activation

To induce B-cell receptor crosslinking, OSU-CLL and MEC-1 were treated with 10 µg/mL of goat F(ab’)<sub>2</sub> anti-human IgM (Jackson ImmunoResearch, West Grove, PA, USA) for the final 15 min of treatment. Cells were then harvested and lysed for immunoblot analyses.

4.5. Inhibitor Washout Assay

OSU-CLL and MEC-1 cells were treated with indicated concentrations of inhibitors or vehicle for 1 h, washed three times with PBS, and incubated in complete culture medium for 3 h. For continuous treatment, the inhibitors or vehicle control remained for the entire treatment duration (4 h). In the final 15 min of treatment, cells were treated with anti-IgM to induce BCR crosslinking as described above and lysed for immunoblot analyses.

4.6. Ex Vivo Stimulation of Primary Malignant B-Cells

Primary CLL cells were cultured with 3.2 µM CpG 2006 oligodeoxynucleotides (Integrated DNA Technologies) to induce proliferation for the duration of treatment. For murine samples, 1 × phorbol 12-myristate 13-acetate (PMA)/ionomycin cell stimulation cocktail (eBioscience, San Diego, CA, USA) was added during treatments.

4.7. Immunoblot Analyses

Cells were treated with indicated concentrations of inhibitors or vehicle control for 4 h under different stimuli. Thereafter, lysates were prepared, analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis, and probed for select proteins. See Supplementary Methods for details.

4.8. Migration Assay

Following 1 h pre-treatment with DMSO, SRX3305, or ibrutinib, MEC-1 cells were placed onto 5-micron trans-well inserts (Corning, Tewksbury, MA, USA) resting in wells containing 200 ng/mL CXCL-12 or 1000 ng/mL CXCL-13 (PeproTech, Cranbury, NJ, USA). No chemokine control wells were included for each treatment condition. After incubating for 6 h, trans-well inserts were carefully removed, and the number of cells that migrated through the insert towards the chemokines were counted by flow cytometry. Data were analyzed using NovoExpress software (ACEA Biosciences Inc., San Diego, CA, USA).

4.9. Statistical Analyses

Differences in cell viability and apoptosis between conditions of interest were assessed using ANOVA models. Dunnett’s test was used to compare conditions and dose levels with vehicle control. A test of linear trend for SRX3305 dosing was performed by employing orthogonal polynomial contrast coefficients. Log-transformations of the data were applied, when necessary, before modeling to stabilize variances specifically for data analyzed as
raw absorption. Percent proliferation data or percent viable data were analyzed without transformation. Data are represented as mean ± SEM. Analyses were conducted using SAS/STAT software, version 9.4 of the SAS System for Windows (SAS Institute Inc., Cary, NC, USA). p-values < 0.05 were considered statistically significant.

5. Conclusions

The novel BTK/PI3K/BRD4 inhibitor, SRX3305, demonstrates marked anti-tumor properties in preclinical models of CLL. Importantly, the pro-survival, proliferative, therapy-resistant, and activation effects promoted by TME sanctuaries were abrogated by SRX3305, which furthermore blocked CLL cell chemotaxis. Additionally, SRX3305 sustained impressive anti-tumor effects in ibrutinib-resistant CLL cells and effectively attenuated alternative/downstream survival signaling pathways. Together, these findings provide strong rationale for the clinical development of this distinct triple-action inhibitor for treating B-cell lymphoproliferative diseases, especially in the relapse/refractory setting.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms23126712/s1.

Author Contributions: A.L.S., A.P.E., S.A.S., D.Y.M., L.T.U. and D.E.-G. performed experiments and acquired and/or analyzed the data; L.M.S. and E.R.L. assisted with the statistical analysis; A.L.S., T.G.K. and D.E.-G. contributed to the conceptualization, experimental design, and interpretation of the results; C.R.D., A.K. and J.M.V. provided critical translational insight that helped shape the discussion of the research; A.L.S. and D.E.-G. wrote the original manuscript draft and obtained input from all other authors who reviewed and edited the manuscript. D.E.-G. managed and supervised the study and obtained funding. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by institutional funds from the University of Nebraska Medical Center (D.E.-G.).

Institutional Review Board Statement: Primary PBMCs from CLL patients were obtained from the Leukemia Tissue Bank at The Ohio State University Comprehensive Cancer Center in accordance with the Declaration of Helsinki following informed consent under approved Institutional Review Board protocol (#1997C0194). The samples were de-identified and used for the in vitro experiments outlined in this study. Primary murine tumor samples were obtained through an approved institutional animal care and use committee protocol at UNMC (#1816901FC).

Informed Consent Statement: Patients provided informed consent for the use of their biologic specimens for research purposes according to institutional guidelines.

Data Availability Statement: The structures of SRX3305 or SRX3262 used in this study are proprietary information of SignalRx Pharmaceuticals, Inc. (Patent number WO2020023340A1, 2020) [36] and are not publicly available. All other data will be made available from the authors upon reasonable request.

Acknowledgments: We thank SignalRx Pharmaceuticals, Inc. for providing SRX3305 and SRX3262 and Donald L. Durden for discussion. The authors also thank The Ohio State University Leukemia Tissue Bank staff for primary patient sample procurement services that was supported by the National Cancer Institute Grant P30 CA016058. The authors acknowledge Biorender.com, which was used to create the graphical abstract.

Conflicts of Interest: A.L.S., A.P.E., S.A.S, D.Y.M., L.T.U., L.M.S., E.R.L., A.K., T.G.K. and D.E-G. have no conflict of interest. C.R.D. has served on an advisory board for TG Therapeutics. J.M.V. has received honoraria from AbbVie, Janssen Pharmaceuticals, AstraZeneca, MEI Pharma, Johnson & Johnson, Pharmacyclics, Genentech, Inc., MorphoSys, and Lilly.

References
1. Kipps, T.J.; Stevenson, F.; Wu, C.J.; Croce, C.M.; Packham, G.; Wierda, W.G.; O’Brien, S.; Gribben, J.; Rai, K. Chronic lymphocytic leukaemia. Nat. Rev. Dis. Prim. 2017, 3, 16096. [CrossRef]
2. Riches, J.C.; Gribben, J.G. Understanding the immunodeficiency in chronic lymphocytic leukemia: Potential clinical implications. Hematol. Oncol. Clin. N. Am. 2013, 27, 207–235. [CrossRef] [PubMed]
3. Hallek, M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am. J. Hematol. 2019, 94, 1266–1287. [CrossRef] [PubMed]

4. Herman, S.E.M.; Gordon, A.L.; Hertlein, E.; Ramanunni, A.; Zhang, X.; Jaglowski, S.; Flynn, J.; Jones, J.; Blum, K.A.; Buggy, J.J.; et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117, 6287–6296. [CrossRef] [PubMed]

5. Herman, S.E.; Jones, J.; Mustafa, R.Z.; Farooqui, M.; Wiestner, A. In Vivo Effects of Ibrutinib on the Migration of Chronic Lymphocytic Leukemia Cells Differ Between Patients and Reduce the Ability of the Bone Marrow Microenvironment to Attract the Tumor Cells. Blood 2013, 122, 604. [CrossRef]

6. O’Brien, S.; Furman, R.R.; Coutre, S.; Flinn, I.W.; Burger, J.A.; Blum, K.; Sharman, J.; Wierda, W.; Jones, J.; Zhao, W.; et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: A 5-year experience. Blood 2018, 131, 1910–1919. [CrossRef]

7. Zhao, X.; Liu, T.; Silva, A.; Shah, B.; Tao, J.; Fang, B.; Zhang, L.; Fu, K.; Bi, C.; Li, J.; et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat. Commun. 2017, 8, 14920. [CrossRef]

8. Rahal, R.; Frick, M.; Romero, R.; Korn, J.M.; Kridel, R.; Chan, F.C.; Meissner, B.; Bhang, H.-E.; Ruddy, D.; Kauffmann, A.; et al. Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma. Nat. Med. 2014, 20, 87–92. [CrossRef]

9. Moyo, T.K.; Wilson, C.S.; Moore, D.J.; Eischen, C.M. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition. Oncogene 2017, 36, 4653–4661. [CrossRef]

10. Lee, J.; Zhang, L.L.; Wu, W.; Guo, H.; Li, Y.; Alikhan, M.; Venkataraman, G.; Huang, S.; Zhang, H.; Alikhan, M.; et al. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv. 2018, 2, 2039–2051. [CrossRef]

11. Ahn, I.E.; Underbayev, C.; Albitar, A.; Herman, S.E.M.; Tian, X.; Maric, I.; Arthur, D.C.; Wake, L.; Pittaluga, S.; Yuan, C.M.; et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 2017, 129, 1469–1479. [CrossRef] [PubMed]

12. George, B.; Chowdhury, S.M.; Hart, A.; Sircar, A.; Singh, S.K.; Nath, U.K.; Mamgain, M.; Singh, N.K.; Sehgal, L.; Jain, N. ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas. Cancers 2020, 12, 1328. [CrossRef] [PubMed]

13. Rossi, D.; Spina, V.; Gaidano, G. Biology and treatment of Richter syndrome. Blood 2018, 131, 2761–2772. [CrossRef] [PubMed]

14. Skånland, S.S.; Mato, A.R. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. Blood Adv. 2021, 5, 334–343. [CrossRef]

15. Timofeeva, N.; Gandhi, V. Ibrutinib combinations in CLL therapy: Scientific rationale and clinical results. Blood Cancer J. 2021, 11, 79. [CrossRef]

16. Baylin, S.B.; Jones, P.A. A decade of exploring the cancer epigenome—Biological and translational implications. Nat. Rev. Cancer 2011, 11, 726–734. [CrossRef]

17. Mansouri, L.; Wierzbinska, J.A.; Plass, C.; Rosenquist, R. Epigenetic deregulation in chronic lymphocytic leukemia: Clinical and biological impact. Semin. Cancer Biol. 2018, 51, 1–11. [CrossRef]

18. Xanthopoulous, C.; Kostareli, E. Advances in Epigenetics and Epigenomics in Chronic Lymphocytic Leukemia. Curr. Genet. Med. Rep. 2019, 7, 214–226. [CrossRef]

19. Jiang, Y.; Redmond, D.; Nie, K.; Eng, K.W.; Clozel, T.; Martin, P.; Tan, L.H.; Melnick, A.M.; Tam, W.; Elemento, O. Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biol. 2014, 15, 432. [CrossRef]

20. Filippakopoulos, P.; Knapp, S. Targeting bromodomains: Epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 2014, 13, 337–356. [CrossRef]

21. Hnisz, D.; Abraham, B.; Lee, T.I.; Lau, A.; Saint-André, V.; Sigova, A.A.; Hoke, H.A.; Young, R.A. Super-Enhancers in the Control of Cell Identity and Disease. Cell 2013, 155, 934–947. [CrossRef] [PubMed]

22. Lovén, J.; Hoke, H.A.; Lin, C.Y.; Lau, A.; Orlando, D.A.; Vakoc, C.R.; Bradner, J.E.; Lee, T.I.; Young, R.A. Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers. Cell 2013, 153, 320–334. [CrossRef] [PubMed]

23. Chapuy, B.; McKeown, M.R.; Lin, C.Y.; Monti, S.; Roemer, M.G.; Qi, J.; Rahl, P.B.; Sun, H.H.; Yeda, K.T.; Doench, J.G.; et al. Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma. Cancer Cell 2013, 24, 777–790. [CrossRef] [PubMed]

24. Dawson, M.A.; Prinjha, R.K.; Dittmann, A.; Giotsopoulos, G.; Bantscheff, M.; Chan, W.-I.; Robson, S.C.; Chung, C.-W.; Hopf, C.; Savitski, M.M.; et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478, 529–533. [CrossRef]

25. Hogg, S.J.; Newbold, A.; Vervoort, S.J.; Cluse, L.A.; Martin, B.P.; Gregory, G.P.; Lefebvre, M.; Vidacs, E.; Tothill, R.W.; Bradner, J.E.; et al. BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Mol. Cancer Ther. 2016, 15, 2030–2041. [CrossRef]

26. Huang, B.; Yang, X.-D.; Zhou, M.-M.; Ozato, K.; Chen, L.-F. Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelA. Mol. Cell. Biol. 2009, 29, 1375–1387. [CrossRef]

27. Mansouri, L.; Papakonstantinou, N.; Ntoufa, S.; Stamatopoulos, K.; Rosenquist, R. NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions. Semin. Cancer Biol. 2016, 36, 40–48. [CrossRef]
28. Chaidos, A.; Caputo, V.; Karadimitris, A. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: Emerging preclinical and clinical evidence. *Ther. Adv. Hematol.* **2015**, *6*, 128–141. [CrossRef]

29. Stathis, A.; Bertoni, F. BET Proteins as Targets for Anticancer Treatment. *Cancer Discov.* **2018**, *8*, 24–36. [CrossRef]

30. Ozer, H.G.; El-Gamal, D.; Powell, B.; Hing, Z.A.; Blachly, J.S.; Harrington, B.; Mitchell, S.; Grieselhuber, N.R.; Williams, K.; Lai, T.-H.; et al. BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX5107, a Novel Structurally Distinct BET Inhibitor. *Cancer Discov.* **2018**, *8*, 438–477. [CrossRef]

31. Spriano, F.; Stathis, A.; Bertoni, F. Targeting BET bromodomain proteins in cancer: The example of lymphomas. *Pharmacol. Ther.* **2020**, *215*, 107631. [CrossRef] [PubMed]

32. Kim, E.; Hacken, E.T.; Sivina, M.; Clarke, A.; Thompson, P.A.; Jain, N.; Ferrajoli, A.; Estrov, Z.; Keating, M.J.; Wierda, W.G.; et al. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. *Leukemia* **2019**, *34*, 1588–1598. [CrossRef]

33. Carra, G.; Nicoli, P.; Lingua, M.F.; Maffeo, B.; Cartellà, A.; Circosta, P.; Brancaccio, M.; Parvis, G.; Gaidano, V.; Guerrasio, A.; et al. Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia. *J. Cell. Mol. Med.* **2019**, *24*, 1650–1657. [CrossRef] [PubMed]

34. Tarantelli, C.; Lange, M.; Gaudio, E.; Cascione, L.; Spriano, F.; Kwee, I.; Arribas, A.J.; Rinaldi, A.; Jourdan, T.; Berthold, M.; et al. Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. *Blood Adv.* **2020**, *4*, 819–829. [CrossRef] [PubMed]

35. Fiskus, W.; Mill, C.P.; Perera, D.; Birdwell, C.; Deng, Q.; Yang, H.; Lara, B.H.; Jain, N.; Ferrajoli, A.; et al. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. *Leukemia* **2021**, *35*, 2621–2634. [CrossRef] [PubMed]

36. Morales, G.A.; Garlich, J.R.; Durden, D.L. Single Molecule Compounds Providing Multi-Target Inhibition of Btk and Other Proteins and Methods of Use Thereof. U.S. Patent Application 17/262,358, 30 September 2021.

37. Pal, D.; Vann, K.R.; Joshi, S.; Sahar, N.E.; Morales, G.A.; El-Gamal, D.; Kutateladze, T.G.; Durden, D.L. The BTK/PI3K/BRD4 axis and the LL-100 panel: 100 cell lines for blood cancer studies. *Oncoimmunology* **2012**, *1*, 18–27. [CrossRef] [PubMed]

38. Mehra, S.; Messner, H.; Minden, M.; Changtiti, R.S. Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. *Genes Chromosomes Cancer* **2002**, *33*, 225–234. [CrossRef] [PubMed]

39. Quentmeier, H.; Pommerenke, C.; Dirks, W.G.; Eberth, S.; Koeppel, M.; MacLeod, R.A.; Nagel, S.; Steube, K.; Uphoff, C.C.; Drexler, H.G. The LL-100 Cell Lines Panel: Tool for Molecular Leukemia-Lymphoma Research. *Genet. Mol. Biol.* **2015**, *38*, 463–470. [CrossRef] [PubMed]

40. Quentmeier, H.; Pommerenke, C.; Dirks, W.G.; Eberth, S.; Koeppel, M.; MacLeod, R.A.; Nagel, S.; Steube, K.; Uphoff, C.C.; Drexler, H.G. The LL-100 panel: 100 cell lines for blood cancer studies. *Oncoimmunology* **2012**, *1*, 18–27. [CrossRef] [PubMed]

41. Mehra, S.; Messner, H.; Minden, M.; Changtiti, R.S. Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. *Genes Chromosomes Cancer* **2002**, *33*, 225–234. [CrossRef] [PubMed]

42. Mehra, S.; Messner, H.; Minden, M.; Changtiti, R.S. Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. *Genes Chromosomes Cancer* **2002**, *33*, 225–234. [CrossRef] [PubMed]

43. Quentmeier, H.; Pommerenke, C.; Dirks, W.G.; Eberth, S.; Koeppel, M.; MacLeod, R.A.; Nagel, S.; Steube, K.; Uphoff, C.C.; Drexler, H.G. The LL-100 panel: 100 cell lines for blood cancer studies. *Sci. Rep.* **2019**, *9*, 8218. [CrossRef] [PubMed]

44. Drexler, H.G.; Quentmeier, H.; Gogok, P.; Evaldsson, C.; Myhrinder, A.L.; Hellqvist, E.; Rasul, A.; Björkholm, M.; Jansson, M.; Mansouri, A.; et al. MECL1 and MECL2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia. *PLoS ONE* **2014**, *9*, e106008. [CrossRef]

45. Stachini, A.; Aragno, M.; Vallario, A.; Alfarano, A.; Circosta, P.; Gottardi, D.; Faldella, A.; Rege-Cambrin, G.; Thunberg, U.; Nilsson, K.; et al. MEC1 and MEC2: Two new cell lines derived from B-chronic lymphocytic leukemia in prolymphocytoid transformation. *Leuk. Res.* **1999**, *23*, 127–136. [CrossRef]

46. Rosem, A.; Bergh, A.C.; Circosta, P.; Myhrinder, A.L.; Hellqvist, E.; Rasul, A.; Björkholm, M.; Jansson, M.; Mansouri, A.; et al. Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. *Oncotarget* **2012**, *3*, 18–27. [CrossRef] [PubMed]

47. Mehra, S.; Messner, H.; Minden, M.; Changtiti, R.S. Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. *Genes Chromosomes Cancer* **2002**, *33*, 225–234. [CrossRef] [PubMed]

48. Quentmeier, H.; Pommerenke, C.; Dirks, W.G.; Eberth, S.; Koeppel, M.; MacLeod, R.A.; Nagel, S.; Steube, K.; Uphoff, C.C.; Drexler, H.G. The LL-100 panel: 100 cell lines for blood cancer studies. *Sci. Rep.* **2019**, *9*, 8218. [CrossRef] [PubMed]

49. Drexler, H.G.; Quentmeier, H. The LL-100 Lymphoma Line Panel: Tool for Molecular Leukemia-Lymphoma Research. *Int. J. Mol. Sci.* **2020**, *21*, 5800. [CrossRef]

50. Davis, R.E.; Ngo, V.N.; Lenz, G.; Tolar, P.; Young, R.M.; Romesser, P.B.; Kohlhammer, H.; Lamy, L.; Zhao, H.; Yang, Y.; et al. Chronic active B-cell-receptor signalling in diffuse large b-cell lymphoma. *Nature* **2010**, *463*, 88–92. [CrossRef]

51. Ngo, V.N.; Young, R.M.; Schmitz, R.; Jhavar, S.; Xiao, W.; Lim, K.H.; Kohlhammer, H.; Xu, W.; Yang, Y.; Zhao, H.; et al. Oncogenically active MYD88 as a strategy for human treatment of mantle lymphoma. *Nature* **2011**, *470*, 115–119. [CrossRef]

52. Morin, R.D.; Johnson, N.A.; Severson, T.M.; Mungall, A.J.; An, J.; Goya, R.; Paul, J.E.; Boyle, M.; Woolcock, B.W.; Kuchenbauer, F.; et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinatal-center origin. *Nat. Genet.* **2010**, *42*, 181–185. [CrossRef]

53. Seda, V.; Mraz, M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. *Eur. J. Haematol.* **2014**, *93*, 193–205. [CrossRef]

54. Zhuang, J.; Hawkins, S.F.; Glenn, M.A.; Lin, K.; Johnson, G.G.; Carter, A.; Cawley, J.C.; Pettitt, A.R. Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: The therapeutic potential of Akt inhibition. *Haematologica* **2009**, *95*, 110–118. [CrossRef]

55. Swerdlov, S.H.; Murray, L.J.; Habeshaw, J.A.; Stansfeld, A.G. Lymphocytic lymphoma/B-chronic lymphocytic leukaemia—An immunohistopathological study of peripheral B lymphocyte neoplasia. *Br. J. Cancer* **1984**, *50*, 587–599. [CrossRef]

56. Deckert, T.; Schneller, F.; Sparwasser, T.; Tretter, T.; Lipford, G.B.; Wagner, H.; Peschel, C. Immunostimulatory CpG-oligodeoxynucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukaemia B cells. *Blood* **2000**, *95*, 999–1006. [CrossRef] [PubMed]
52. Abbas, T.; Dutta, A. p21 in cancer: Intricate networks and multiple activities. *Nat. Cancer* 2009, 9, 400–414. [CrossRef] [PubMed]
53. Bichi, R.; Shinton, S.A.; Martin, E.S.; Koval, A.; Calin, G.A.; Cesari, R.; Russo, G.; Hardy, R.R.; Croce, C.M. Human chronic lymphocytic leukemia modeled in mouse by targeted TCI1 expression. *Proc. Natl. Acad. Sci. USA* 2002, 99, 6955–6960. [CrossRef]
54. Johnson, A.J.; Lucas, D.M.; Muthusamy, N.; Smith, L.L.; Edwards, R.B.; De Lay, M.D.; Croce, C.M.; Grever, M.R.; Byrd, J.C. Characterization of the TCI-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. *Blood* 2006, 108, 1334–1338. [CrossRef] [PubMed]
55. Rogers, K.A.; El-Gamal, D.; Bonnie, H.K.; Zachary, H.A.; Virginia, G.M.; Rose, M.; Smith, L.L.; Yu, L.; Johnson, A.J.; Byrd, J.C.; et al. The Eμ-Myc/TCI1 Transgenic Mouse as a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing. *Blood* 2015, 126, 2752. [CrossRef]
56. Lucas, F.; Rogers, K.A.; Harrington, B.K.; Pan, A.; Yu, L.; Breitbach, J.; Bundschuh, R.; Goettl, V.M.; Hing, Z.A.; Kanga, P.; et al. Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. *Clin. Cancer Res.* 2019, 25, 6260–6273. [CrossRef]
57. Herishanu, Y.; Katz, B.-Z.; Lipsky, A.; Wiestner, A. Biology of Chronic Lymphocytic Leukemia in Different Microenvironments. *Hematol. Clin. N. Am.* 2013, 27, 173–206. [CrossRef]
58. Ramsay, A.D.; Rodriguez-Justo, M. Chronic lymphocytic leukaemia—The role of the microenvironment pathogenesis and therapy. *Br. J. Haematol.* 2013, 162, 15–24. [CrossRef]
59. Kurtova, A.V.; Balakrishnan, K.; Chen, R.; Ding, W.; Schnabl, S.; Quiroga, M.P.; Sivina, M.; Wierda, W.G.; Estrov, Z.; Keating, M.J.; et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: Development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. *Blood* 2009, 114, 4441–4450. [CrossRef]
60. Burger, J.A.; Wiestner, A. Targeting B cell receptor signalling in cancer: Preclinical and clinical advances. *Nat. Cancer* 2018, 18, 148–167. [CrossRef]
61. Hartmann, T.N.; Grabovsky, V.; Wang, W.; Desch, P.; Rubenzer, G.; Wollner, S.; Binsky, I.; Vallon-Eberhard, A.; Sapoznikov, A.; Burger, M.; et al. Circulating B-Cell Chronic Lymphocytic Leukemia Cells Display Impaired Migration to Lymph Nodes and Bone Marrow. *Cancer Res.* 2009, 69, 3121–3130. [CrossRef] [PubMed]
62. Scielzo, C.; Bertilaccio, M.T.S.; Simonetti, G.; Dagklis, A.; Hacken, E.T.; Fazi, C.; Muzio, M.; Catifalé, V.; Kitamura, D.; Restuccia, U.; et al. HS1 has a central role in the trafficking and homing of leukemic B cells. *Blood* 2010, 116, 3537–3546. [CrossRef] [PubMed]
63. Burger, J.A.; Burger, M.; Kipps, T.J. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. *Blood* 1999, 94, 3658–3667. [CrossRef] [PubMed]
64. Ansel, K.; Harris, R.B.; Cyster, J.G. CXCL13 Is Required for B1 Cell Homing, Natural Antibody Production, and Body Cavity Immunity. *Immunity* 1999, 10, 463–471. [CrossRef]
65. Ponader, S.; Chen, S.-S.; Buggy, J.J.; Gandhi, V.; Wierda, W.G.; Keating, M.J.; O’Brien, S.; Chiorazzi, N.; Burger, M.; et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. *Blood* 2012, 119, 1182–1189. [CrossRef]
66. Spina, V.; Forestieri, G.; Zucchetto, A.; Bruscaggin, A.; Bittolo, T.; Di Bergamo, L.T.; Sennes, E.; Condoluci, A.; Tissino, E.; De Paoli, L.; et al. Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia. *Blood* 2018, 132, 585. [CrossRef]
67. Dubois, N.; Crompt, E.; Meuleman, N.; Bron, D.; Lagneaux, L.; Stamatopoulos, B. Importance of Cxcl13 and Cxcr4 in Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles. *Front. Oncol.* 2020, 10, 1422. [CrossRef]
68. Shain, K.H.; Dalton, W.S.; Tao, J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. *Oncogene* 2015, 34, 4673–4682. [CrossRef]
69. De Rooij, M.F.M.; Kuil, A.; Geest, C.R.; Eldering, E.; Chang, B.Y.; Buggy, J.J.; Pals, S.T.; Spaargaren, M. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. *Blood* 2012, 119, 2590–2594. [CrossRef]
70. Hoellenriegel, J.; Meadows, S.A.; Sivina, M.; Wierda, W.G.; Kantarjian, H.; Keating, M.J.; Giese, N.; O’Brien, S.; Yu, A.; Miller, L.L.; et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. *Blood* 2011, 118, 3603–3612. [CrossRef] [PubMed]
71. Chen, Z.-Q.; Cao, Z.-R.; Wang, Y.; Zhang, X.; Xu, L.; Wang, Y.-X.; Chen, Y.; Yang, C.-H.; Ding, J.; Meng, L.-H. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma. *Cancer Lett.* 2021, 524, 206–218. [CrossRef] [PubMed]
72. Derenzini, E.; Mondello, P.; Erazo, T.; Portelina, A.; Liu, Y.; Scallion, M.; Asgari, Z.; Philip, J.; Hilden, P.; Valli, D.; et al. BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors. *Cell Rep.* 2018, 24, 2155–2166. [CrossRef] [PubMed]
73. Sears, R.; Nuckolls, F.; Haura, E.; Taya, Y.; Tamai, K.; Nevins, J.R. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. *Genes Dev.* 2000, 14, 2501–2514. [CrossRef]
74. Zhu, J.; Blenis, J.; Yuan, J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. *Proc. Natl. Acad. Sci. USA* 2008, 105, 6584–6589. [CrossRef]
76. Schaffer, M.; Chaturvedi, S.; Davis, C.; Aquino, R.; Stepanchick, E.; Versele, M.; Liu, Y.; Yang, J.; Lu, R.; Balasubramanian, S. Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen. *Leuk. Lymphoma* **2017**, *23*, 59, 931–940. [CrossRef]

77. Niemann, C.U.; Mora-Jensen, H.I.; Dadashian, E.L.; Krantz, F.; Covey, T.; Chen, S.-S.; Chiorazzi, N.; Izumi, R.; Ulrich, R.; Lannutti, B.J.; et al. Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. *Clin. Cancer Res.* **2017**, *23*, 5814–5823. [CrossRef]

78. Andrews, F.H.; Singh, A.R.; Joshi, S.; Smith, C.A.; Morales, G.A.; Garlich, J.R.; Durden, D.L.; Kutateladze, T.G. Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E1072–E1080. [CrossRef]

79. Sestier, M.; Hillis, C.; Fraser, G.; Leong. D. Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation. *Curr. Oncol. Rep.* **2021**, *23*, 113. [CrossRef]

80. Lampson, B.L.; Brown, J.R. The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. *Hematol. Clin. N. Am.* **2021**, *35*, 807–826. [CrossRef]

81. Falchook, G.; Rosen, S.; LoRusso, P.; Watts, J.; Gupta, S.; Coombs, C.C.; Talpaz, M.; Kurzrock, R.; Mita, M.; Cassaday, R.; et al. Development of 2 Bromodomain and Extraterminal Inhibitors with Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. *Clin. Cancer Res.* **2020**, *26*, 1247–1257. [CrossRef] [PubMed]

82. Piha-Paul, S.A.; Sachdev, J.C.; Barve, M.; Lorusso, P.; Szmulewitz, R.; Patel, S.P.; Lara, P.N., Jr.; Chen, X.; Hu, B.; Freise, K.J.; et al. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. *Clin. Cancer Res.* **2019**, *25*, 6309–6319. [CrossRef] [PubMed]

83. Davids, M.S.; Kim, H.T.; Nicoitra, A.; Savell, A.; Francoeur, K.; Hellman, J.M.; Bazemore, J.; Miskin, H.P.; Sportelli, P.; Stampleman, L.; et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: A multicentre phase 1–1b study. *Lancet Haematol.* **2018**, *6*, e38–e47. [CrossRef]

84. Matulonis, U.A.; Wulf, G.M.; Barry, W.T.; Birrer, M.; Westin, S.N.; Farooq, S.; Bell-McGuinn, K.M.; Obermayer, E.; Whalen, C.; Spagnoletti, T.; et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKMI20 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. *Ann. Oncol.* **2017**, *28*, 512–518. [CrossRef]

85. Hertlein, E.; Beckwith, K.A.; Lozanski, G.; Chen, T.L.; Towns, W.H.; Johnson, A.J.; Lehman, A.; Ruppert, A.S.; Bolon, B.; Andritsos, L.; et al. Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease. *PloS ONE* **2013**, *8*, e76607. [CrossRef]

86. Yamada, Y.; Sakurada, K.; Takeda, Y.; Gojo, S.; Umezawa, A. Single-cell-derived mesenchymal stem cells overexpressing Csx/Nkx2.5 and GATA4 undergo the stochastic cardiomyogenic fate and behave like transient amplifying cells. *Exp. Cell Res.* **2007**, *313*, 698–706. [CrossRef]